Streetbeat News

Stock Prices

PRLD

Prelude Therapeutics has presented preliminary results from a Phase 1 study of PRT2527, showing activity in relapsed/refractory lymphoid malignancies, including those previously treated with CAR-T therapy.

Portfolio Pulse from

December 11, 2024 | 12:45 pm

RCL

Royal Caribbean Group has announced a 38% increase in its quarterly dividend, now set at $0.55 per share, payable on January 13, 2025. This move reflects the company's confidence in its financial health and future prospects.

Portfolio Pulse from

December 11, 2024 | 12:45 pm

LLOY

Lloyds Banking Group shares rose after the Supreme Court agreed to hear an appeal on a motor finance mis-selling case, potentially affecting compensation liabilities.

Portfolio Pulse from

December 11, 2024 | 12:45 pm

XRX

Levi & Korsinsky is inviting shareholders who lost money on Xerox Holdings Corporation (NASDAQ:XRX) to join a class action lawsuit for potential recovery under federal securities laws.

Portfolio Pulse from

December 11, 2024 | 12:45 pm

AEHR

Levi & Korsinsky has filed a securities class action lawsuit on behalf of Aehr Test Systems, Inc. (NASDAQ:AEHR) shareholders. Investors who suffered losses can seek potential recovery under federal securities laws.

Portfolio Pulse from

December 11, 2024 | 12:45 pm

ZETA

Levi & Korsinsky has filed a securities class action lawsuit on behalf of Zeta Global Holdings Corp. (NYSE:ZETA) shareholders. Investors who suffered losses can seek potential recovery under federal securities laws.

Portfolio Pulse from

December 11, 2024 | 12:45 pm

ADCT

ADC Therapeutics announced positive initial data from its LOTIS-7 clinical trial, showing that ZYNLONTA in combination with glofitamab is effective in treating relapsed/refractory diffuse large B-cell lymphoma, with a 94% overall response rate and 72% complete response rate. The treatment showed no dose-limiting toxicities or severe side effects.

Portfolio Pulse from

December 11, 2024 | 12:45 pm

MAPS

Investors in WM Technology, Inc. (NASDAQ:MAPS) are encouraged to contact Levi & Korsinsky by December 16, 2024, to discuss potential recovery options under federal securities laws due to investment losses.

Portfolio Pulse from

December 11, 2024 | 12:45 pm

AIM

The Kellner Group, led by Ted Kellner, is challenging the current Board of Directors of AIM Immunotech Inc. due to the failure of its clinical strategy. They aim to bring accountability and change to the company's leadership.

Portfolio Pulse from

December 11, 2024 | 12:45 pm

ASML

Levi & Korsinsky has notified shareholders of ASML Holding N.V. about a class action lawsuit and an upcoming deadline for potential recovery under federal securities laws.

Portfolio Pulse from

December 11, 2024 | 12:45 pm